Category Archives: Cell Therapy

Stem Cell Therapy Testimonial - Hair loss treatment 1-888-545-4333
Stem Cell Therapy Testimonial - Hair loss treatment 1-888-545-4333

By: Bofitmiami

Excerpt from:
Stem Cell Therapy Testimonial - Hair loss treatment 1-888-545-4333 - Video

Stem Cell Therapy With Bob - Thomas Schwarzl - SBI - Runner up 2013
Tom is a science punk from the Alps doing his PhD with Systems Biology Ireland. He likes to challenge everything, discover patterns in high complex problems and making them clear for everyone to understand. Besides his scientific interest in stem cell therapy and cancer research, he likes Post Secret, street art, and is planning a start-up after his PhD.

By: thesisin3

Excerpt from:
Stem Cell Therapy With Bob - Thomas Schwarzl - SBI - Runner up 2013 - Video

Autism after stem cell therapy
He is a known case of Autism with history of CIAB, but thereafter parents noticed delayed motor milestones in him along with delayed speech and hyperactivity. So at 2 ½ years, he was diagnosed to have Autism and put on rehabilitation program including Occupational Therapy, Physiotherapy and speech therapy. Neurologically, he has near normal tone and reflexes. On examination, he has all sensation intact and no motor weakness. He has normal vision, hearing but bisyllable speech. He has social isolation. He has no bowel and bladder control and has bed wetting present. Functionally, he needs supervision in all ADL and wheel chair bound for mobility On FIM scores he scores 62 On ISAA he scores 130 Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Read this article:
Autism after stem cell therapy - Video

Stem Cell Therapy for Spinal Cord Injury
He is a paraplegic has history of fall from height in 1993, leading to fracture D4 and paraplegia with complete bowel bladder loss. He was managed conservatively and has been undergoing rehabilitation since then. Neurologically, he is hypertonic and hyperflexic. On examination: he has sensory loss below T4. He has grade 0 muscle power in bilateral lower extremity and near normal upper extremity. He has no bowel and bladder control and is on condom catheter. He has bilateral knee flexion contracture =10. On ASIA impairment scale he scores #39;A #39;. On investigation: MRI: 6/7/2012: Wedge compression of the D4 vertebral body with a focal area of scarring within the spinal canal involving the arachnoid and the spinal cord at D3-4 level. A large cord syrinx extending cranially upto C4vetebral level with a smaller syrinx extending caudally up to D7 vertebral level. EMG / SSEP: It is suggestive of a severe lesion affecting the posterior column conduction from both lower limbs. There is evidence of predominantly Upper motor neurone lesion affecting the lower limbs. Functionally, he needs assistance in most ADL and wheel chair bound for mobility. Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Visit link:
Stem Cell Therapy for Spinal Cord Injury - Video

Norman Receives Stemlogix Stem Cell Therapy - Continued
This video shows a more in-depth look at Norman, a chocolate lab, who has received stemlogix stem cell therapy at the County Animal Clinic. VIDEO COURTESY OF WLIO TV LIMA OHIO

By: StemLogixLLC

Continued here:
Norman Receives Stemlogix Stem Cell Therapy - Continued - Video

MSI 2nd Look - Post Stem Cell Therapy
Buyer came to VOSM in 2009 with medial shoulder instability. He had stem cell injections in the spring and came back in the summer for a second look scope. The shoulder tissue had repaired and regenerated.

By: VetSportsMedicine

Read the rest here:
MSI 2nd Look - Post Stem Cell Therapy - Video

Norman #39;s Stemlogix Stem Cell Therapy Treatment at County Animal Clinic
This is a video of live news coverage courtesy of WHIO TV of Dayton, Ohio. NORMAN A 5 YEAR OLD BLACK LAB SUFFERED A STROKE, AND WAS BROUGHT TO THE COUNTY ANIMAL CLINIC FOR A STEMLOGIX STEM CELL TREATMENT. THIS CREATED QUITE A BIT OF INTEREST FROM THE NEWS MEDIA. NOW AFTER 2 INFUSIONS NORMAN IS ALREADY SHOWING SIGNS OF RECOVERY.

By: StemLogixLLC

Read the original post:
Norman's Stemlogix Stem Cell Therapy Treatment at County Animal Clinic - Video

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad technology platform.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

VC-01 is a very promising, development-stage product that consists of pancreatic precursor cells (called PEC-01) derived from a proprietary human embryonic stem cell line and encapsulated in a proprietary, immune isolating medical device (the ENCAPTRA device). When implanted under the skin in suitable animal models, the cells further differentiate into insulin producing and other endocrine cells that regulate blood glucose in a manner similar or identical to a normal pancreas. If VC-01 performs in humans as it has in animal studies, it could effectively cure type 1 diabetics and be an important new therapy for insulin dependent type 2 diabetics.

ViaCyte's significant intellectual property portfolio now includes over 300 issued patents and pending applications related to the growth, directed differentiation and use of human pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem cells. This portfolio includes 51 issued U.S. and foreign patents specifically directed to the Company's VC-01 product. In addition to the protection afforded by patents, the Company also relies on significant proprietary know-how to develop its product offerings.

Dr. Paul Laikind, ViaCyte's president and chief executive officer said, "Our comprehensive and growing intellectual property portfolio helps to establish us as a leading company in the cell therapy and regenerative medicine field. Although the Company's resources are currently fully committed to the rapid development of VC-01 as a potentially transformative treatment for patients with insulin-dependent diabetes, our platform technology has many other important applications."

In July and August of 2012, the Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office (the "Board") also issued two decisions favoring ViaCyte on motions filed in the patent interference proceedings between ViaCyte and Geron Corporation (Menlo Park, California). The interferences involved ViaCyte's U.S. Patent No. 7,510,876 ("876 Patent"), which is directed to human definitive endoderm cell cultures in vitro. The Board upheld the claims of ViaCyte's '876 Patent in its entirety over Geron's applications. In September 2012, Geron appealed this decision in the United States District Court for the Northern District of California.

About ViaCyteViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

Visit link:
ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012